BioNTech SE (NASDAQ: BNTX) reported Q2 EPS of EUR6.45. Revenue for the quarter came in at EUR3.2 billion.

The company reiterated BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billion.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.